These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 30772732)

  • 1. Real-world effectiveness of antipsychotic monotherapy and polytherapy in 1543 patients with acute-phase schizophrenia.
    Hatta K; Hasegawa H; Imai A; Sudo Y; Morikawa F; Katayama S; Watanabe H; Ishizuka T; Nakamura M; Misawa F; Fujita K; Ozaki S; Umeda K; Nakamura H; Sawa Y; Sugiyama N;
    Asian J Psychiatr; 2019 Feb; 40():82-87. PubMed ID: 30772732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary.
    Katona L; Czobor P; Bitter I
    Schizophr Res; 2014 Jan; 152(1):246-54. PubMed ID: 24275583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.
    Hatta K; Otachi T; Fujita K; Morikawa F; Ito S; Tomiyama H; Abe T; Sudo Y; Takebayashi H; Yamashita T; Katayama S; Nakase R; Shirai Y; Usui C; Nakamura H; Ito H; Hirata T; Sawa Y;
    Schizophr Res; 2014 Sep; 158(1-3):213-22. PubMed ID: 25086659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial.
    Constantine RJ; Andel R; McPherson M; Tandon R
    Schizophr Res; 2015 Aug; 166(1-3):194-200. PubMed ID: 26141142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone.
    Suzuki T; Uchida H; Watanabe K; Nakajima S; Nomura K; Takeuchi H; Tanabe A; Yagi G; Kashima H
    Hum Psychopharmacol; 2008 Aug; 23(6):455-63. PubMed ID: 18537222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching and augmentation strategies for antipsychotic medications in acute-phase schizophrenia: latest evidence and place in therapy.
    Hatta K; Sugiyama N; Ito H
    Ther Adv Psychopharmacol; 2018 Jun; 8(6):173-183. PubMed ID: 29854396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia.
    Suzuki T; Uchida H; Tanaka KF; Nomura K; Takano H; Tanabe A; Watanabe K; Yagi G; Kashima H
    Int J Neuropsychopharmacol; 2004 Jun; 7(2):133-42. PubMed ID: 14741059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-treatment six-week study of the clinical effectiveness of Paliperidone Palmitate in schizophrenia: data from acute units in Spain (SHADOW study).
    Parellada E; Bioque M; Serrano M; Herrera B; García Dorado M;
    Int J Psychiatry Clin Pract; 2018 Sep; 22(3):191-199. PubMed ID: 29161951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia.
    Tandon R; Belmaker RH; Gattaz WF; Lopez-Ibor JJ; Okasha A; Singh B; Stein DJ; Olie JP; Fleischhacker WW; Moeller HJ;
    Schizophr Res; 2008 Mar; 100(1-3):20-38. PubMed ID: 18243663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical pharmacotherapy for acute schizophrenia patients.
    Hatta K
    Psychiatry Clin Neurosci; 2015 Nov; 69(11):674-85. PubMed ID: 26037685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia.
    Haro JM; Salvador-Carulla L
    CNS Drugs; 2006; 20(4):293-301. PubMed ID: 16599647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study.
    Baandrup L; Gasse C; Jensen VD; Glenthoj BY; Nordentoft M; Lublin H; Fink-Jensen A; Lindhardt A; Mortensen PB
    J Clin Psychiatry; 2010 Feb; 71(2):103-8. PubMed ID: 19895781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries.
    Barbui C; Nosè M; Mazzi MA; Thornicroft G; Schene A; Becker T; Bindman J; Leese M; Helm H; Koeter M; Weinmann S; Tansella M
    Int Clin Psychopharmacol; 2006 Nov; 21(6):355-62. PubMed ID: 17012982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
    Goodwin G; Fleischhacker W; Arango C; Baumann P; Davidson M; de Hert M; Falkai P; Kapur S; Leucht S; Licht R; Naber D; O'Keane V; Papakostas G; Vieta E; Zohar J
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Explicit versus implicit review to explore combination antipsychotic prescribing.
    Wheeler A
    J Eval Clin Pract; 2009 Aug; 15(4):685-91. PubMed ID: 19674220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy.
    Fisher MD; Reilly K; Isenberg K; Villa KF
    BMC Psychiatry; 2014 Nov; 14():341. PubMed ID: 25433495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for Early Non-response to Antipsychotic Drugs in the Treatment of Acute-phase Schizophrenia.
    Hatta K; Ito H
    Clin Psychopharmacol Neurosci; 2014 Apr; 12(1):1-7. PubMed ID: 24851115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.